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ARTICLEPublic Opinion about the Importance
of Privacy in Biobank Research
David J. Kaufman,1,* Juli Murphy-Bollinger,1 Joan Scott,1 and Kathy L. Hudson1
Concerns about privacy may deter people from participating in genetic research. Recruitment and retention of biobank participants
requires understanding the nature andmagnitude of these concerns. Potential participants in a proposed biobank were asked about their
willingness to participate, their privacy concerns, informed consent, and data sharing. A representative survey of 4659 U.S. adults was
conducted. Ninety percent of respondents would be concerned about privacy, 56% would be concerned about researchers having their
information, and 37%would worry that study data could be used against them. However, 60%would participate in the biobank if asked.
Nearly half (48%) would prefer to provide consent once for all research approved by an oversight panel, whereas 42% would prefer to
provide consent for each project separately. Although 92% would allow academic researchers to use study data, 80% and 75%, respec-
tively, would grant access to government and industry researchers. Concern about privacy was related to lower willingness to participate
only when respondents were told that they would receive $50 for participation and would not receive individual research results back.
Among respondents who were told that they would receive $200 or individual research results, privacy concerns were not related to will-
ingness. Survey respondents valued both privacy and participation in biomedical research. Despite pervasive privacy concerns, 60%
would participate in a biobank. Assuring research participants that their privacy will be protected to the best of researchers’ abilities
may increase participants’ acceptance of consent for broad research uses of biobank data by a wide range of researchers.Introduction
Large, prospective cohort studies that use DNA samples
annotated with varying amounts of medical, lifestyle, and
environmental information are becoming standard
research tools for examining the effects of genes, environ-
ment, and lifestyle on common complex diseases,1–5 but
participants’ concerns about the privacy of their informa-
tionmay interfere with recruitment of the large representa-
tive samples that are needed.6,7 The privacy of cohort-study
and biobank participants’ information is usually protected
by removal of personal identiﬁers before data are made
available to researchers. Removing ﬁelds that include
names, addresses, birthdates, ages, phone and fax numbers,
driver’s license and identiﬁcation numbers, URLs, IP and
email addresses, photographs, ﬁngerprints, and other
biometric identiﬁers is often viewed as an effective deiden-
tiﬁcation of data.8 However, emerging forensic methods
have shown that a third party with access to a sample of
an individual’s DNA could use DNA sequence data of the
type collected and shared by genetic biobanks to determine
that the sample belongs to a biobank participant.9 If
the DNA data shared by biobanks are accompanied by dei-
dentiﬁed individual-level health data, this method could
lead to a more clear-cut reidentiﬁcation of study partici-
pants and breach of their privacy.10 In order for researchers
to recruit individuals successfully, potential participants
must believe that the privacy and conﬁdentiality of their
information will be adequately protected, believe that the
beneﬁts of participating in researchoutweigh the risks asso-
ciated with potential losses of medical and genetic privacy,
or not be concerned about privacy issues.11The AmericanThe National Institutes of Health (NIH) and other federal
agencies have contemplated the creation of a large biobank
that would recruit a nationwide representative sample of at
least 500,000 people. A proposed study design12 would
establish recruitment sites across the country for the
collection of biospecimens and the performance of a com-
prehensive baseline exam on each participant. Hospital
and outpatient records might be used in corroborating
observed or reported phenotypes. Specimens would be
sent to laboratories where DNAwould be isolated and gen-
otyped. Information from the genetic analyses, residual
biospecimens, and baseline exam data would be deidenti-
ﬁed and stored in a national repository, where they would
be merged with regularly updated clinical data from partic-
ipants for ten or more years, creating a national biobank.
Deidentiﬁed, coded data from the biobank would be made
available to institutional research board (IRB)-approved
investigators for a wide range of analyses.12,13
Most cohort studies and biobanks like the one outlined
above are observational and do not involve experimental
treatments. Participants generally undergo minimally
invasive sample collection with little risk of physical
harm and provide personal information through biolog-
ical samples, physical and other exams, medical records,
or surveys. As in most such cohort studies, participants
in the proposed cohort study would initially sign a consent
form that clearly outlines the data-sharing policies of the
biobank. It has not been determined whether the large
cohort study would seek one-time consent from partici-
pants for all IRB-approved studies, whether it would allow
participants the opportunity to provide separate consents
for each particular study, or whether another model of1Genetics and Public Policy Center, Johns Hopkins University, Washington, DC 20036 USA
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consent, such as approval for broad disease categories or
categories of research, would be used.
If the consent document accurately and clearly reﬂects
the data-sharing policies of the proposed biobank, then
prospective participants have an opportunity to consider
privacy risks and make decisions about participation
accordingly. For those who consent to take part in the
study, most if not all instances of the sharing of partici-
pants’ data by the biobank should be viewed as acceptable.
It is, however, possible to envision instances of data
sharing or release that could be viewed by a participant
as a violation of privacy. Participants may misunderstand
or underestimate the extent to which they have consented
to share their data14–17 and subsequently view some legit-
imate data sharing as a loss of privacy. Large DNA-sequence
data ﬁles that are made publicly available could theoreti-
cally be used by researchers outside of the biobank’s
purview. Finally, unintentional disclosure of biobank study
data could result from carelessness or data theft. As bio-
banks collect increasingly larger amounts of genomic and
other data and grant access to more diverse groups of
researchers and others for a broader range of purposes,
the risk to research participants of signiﬁcant privacy losses
may increase.18
The magnitude of harm occasioned by a violation of
privacy may depend on the types and clinical relevance
of the disclosed data and ﬁndings, the likelihood that the
individual could be identiﬁed from the data, and the addi-
tional harm that could accrue as a result.19 However, even
when an individual cannot be identiﬁed, or his or her
study data cannot be used for harm, the perception of a
loss of medical and genetic privacy may be harmful in
and of itself.20 Failure to maintain research subjects’
personal privacy21 may prevent the subjects from main-
taining and controlling social relationships that are
affected by the information shared. For example, a person
might choose to share different information with his
doctor and his child in order to receive relevant care
from his doctor and minimize worry of his child. The
ability to control who knows what about us allows us to
alter our behavior with different people.22 Losing this
control can erode personal autonomy and the dignity
and worth of individuals.23 Regardless of the actual risk
or magnitude of additional harms, some people will forgo
participating in medical research and avoid seeking
medical care24 and genetic testing25,26 in order to prevent
unwanted disclosures of their medical and genetic infor-
mation.
When the general public considers the importance of
privacy in the context of participation in genetic and other
biomedical research, they may be concerned with several
aspects of the study and how it will protect their personal
information. Concerns about privacy are multifaceted and
may relate to the type(s) of information being collected
and shared, the degree of control that participants will
have over access to their information, the types of
researchers (and other parties) that may have access, as644 The American Journal of Human Genetics 85, 643–654, Novemwell as what, besides research, could be done with the
personal information for harm or exploitation of study
participants. Much of the existing literature on the impor-
tance of privacy in clinical genetics and genetic research
has focused on the last of these facets, in large part because
of the risks and concerns about employment and insur-
ance discrimination against individuals, group discrimina-
tion based on genotype frequencies, and the implications
of a patient’s clinically relevant genetic information for
family members. This body of work has consistently
shown that use of clinical genetic services is tempered
by public fears that a loss of genetic privacy may result
in discriminatory decisions by employers or insurers.27
Studies of potential genetic-research participants,28
patients,29 and publics30 interested in genetic testing and
of physicians who might refer patients for genetic tests31
all showed a reluctance to submit to testing or to refer
patients for genetic testing because of fears about privacy
violations. A small number of studies have examined
privacy concerns related to participation in genetic
research that would collect, analyze, and store participants’
DNA samples. Findings about the relationship between
privacy concerns and willingness to participate in genetic
research varied considerably, but in nearly every study,
privacy or conﬁdentiality was mentioned as a primary
concern of participants.14,15,17,32–37
In order to assess the importance of privacy concerns in
the public’s support for and willingness to participate in
the proposed national cohort study, how these concerns
weigh against the potential beneﬁts of participation, and
whether privacy concerns relate to people’s preferences
about aspects of the study design, including how consent
is obtained, who collects study data, and with whom the
data are shared, we carried out a national survey of the
general public. In addition to measuring concern about
the potential for misuse of participants’ personal informa-
tion and study data, the survey also measured the relative
importance of protecting genetic information in compar-
ison to other types of health and personal information
and whether concerns about privacy are related to the afﬁl-
iation (academic, government, or industry) of researchers
who might use or see cohort study data.
Subjects and Methods
On the basis of themes emerging from 15 focus groups,13,38 a 177-
item online survey was drafted for the collection of data on public
opinions about the proposed national cohort study. A large pilot
study was ﬁelded for evaluation of the online survey for length
and clarity. Sample selection and survey administration were
managed by the ﬁrm Knowledge Networks (KN).39 A total of
7978 potential participants 18 years of age and older were
randomly sampled from KN’s panel of U.S. residents, including
oversamples of black non-Hispanics, Hispanics, and people living
outside ofmetropolitan statistical areas. KN selects itsmaster panel
by using list-assisted random-digit dialing to provide a probability-
based sample to draw from. The main survey was ﬁelded onlineber 13, 2009
between December 14, 2007, and January 31, 2008. Information
previously collected by KN regarding panel members’ demo-
graphics and backgrounds was added to the data set. The survey
was judged by the Johns Hopkins University IRB as imposing
only minimal risks on participants and was qualiﬁed as research
exempt from human subject review (application no. NA-
00014533). The survey ﬁrst asked several general questions about
health care, privacy, and medical records, then participants were
shown a video describing the proposed cohort study. The video
description stated that data collected from cohort-study partici-
pants would be coded before being entered into a national data-
base for use by researchers.40 Respondents were then asked about
their support for the proposed study, concerns about privacy,
preferences about study design, and willingness to participate.
At the end of the survey, respondents were shown one of eight
randomly selected study-design scenarios and asked whether they
would be willing to participate in the cohort study if asked. The
eight scenarios varied with respect to three factors: study burden
(low burden, which consisted of a half-day exam and a yearly
questionnaire, and high burden, which added a home visit by
researchers and diet and exercise journals), return of individual
research results (returned or not), and compensation for participa-
tion ($50 or $200).41 A detailed description of the scenarios and
the deﬁnition provided for the term ‘‘individual research results’’
can be found in the Appendix.
Weights corresponding to U.S. Census demographic bench-
marks were calculated so that the oversamples were accounted
for and bias from sampling error was minimized. Willingness to
participate in the study and opinions about the study were
measured with four-point Likert scales. Data were analyzed in
the SUDAAN software package,42 which permits correction for
the survey sampling scheme when judging hypothesis tests.
Multiple logistic regressionwas used for the examination of demo-
graphic factors associated with beliefs about privacy and associa-
tions between privacy beliefs and people’s willingness to partici-
pate in the study, their preferences regarding sharing samples
and information, and the importance of policies for the protection
of study data. Analyses of the entire data set were adjusted for age
(continuous), education (categorical), household income (categor-
ical), gender, and race or ethnic group.
Results
A total of 7978 people were contacted, and 4659 provided
valid responses, for a response rate of 58.4%. The margin
of error on opinion estimates based on the entire sample
is 5 1.6% after weighting of the data and correction for
sampling design. Demographic characteristics of the
surveyed population are found in Table 1. Both weighted
and unweighted demographic distributions of the sample
were comparable to year 2000 U.S. Census ﬁgures.41
General Beliefs about Privacy
Before survey participants were introduced to the proposed
cohort study, general questions were asked about privacy.
A total of 88% were very or somewhat concerned about
the privacy of their ﬁnancial information, and 79% were
concerned about the privacy of their medical information.
Black non-Hispanics (p¼ 43 104), American Indians andThe AmericanAlaska Natives (p ¼ 0.003), and participants who self-iden-
tiﬁed as being of two or more races (p ¼ 0.04) were all
signiﬁcantly more likely than white non-Hispanics to say
that they were concerned about the privacy of their
medical information (Table 1). Respondents over the age
of 30 were also more likely to express concern about
medical privacy (adjusted p ¼ 0.002). Concern about
medical privacy did not differ signiﬁcantly by income,
education, or gender.
One-third of respondents agreed with the statement that
‘‘some information in medical records is sensitive and
needs extra privacy protections.’’ The remainder agreed
that ‘‘all medical information should have the same
privacy protections.’’ People who felt that some aspects
of a medical record deserve extra protection (n ¼ 1574)
were shown a list of medical-information topics and asked
which (if any) they felt needed extra privacy protection.
(Figure 1) Nearly all respondents felt that social security
numbers deserved extra privacy protection, whereas 44%
would protect genetic test results and 28% were concerned
about family histories.
Nine in ten respondents said that they would be some-
what (26%) or very (64%) concerned about ‘‘protecting
my privacy’’ if they were to take part in the proposed
cohort study. The proportion concerned about protection
of privacy in the study was consistent across all demo-
graphic groups, and most groups were more concerned
about protecting their privacy in the study than about pro-
tecting the privacy of medical records (Table 1). Respon-
dents were also asked about other related concerns. Three
in four were concerned about ‘‘the government having
[their] samples and information,’’ and 56% were con-
cerned about ‘‘researchers having [their] samples and infor-
mation.’’ Black non-Hispanic respondents, women, and
those without a college degree were all signiﬁcantly more
likely to be concerned about both researchers and the
government having access to their personal information
(Table 1). Asian Americans and those with incomes under
$25,000 were signiﬁcantly more likely to say that they
were concerned about study researchers having their
samples. Finally, 37% of respondents said that they would
be afraid that the information collected by the study could
be used against them. Black non-Hispanics and partici-
pants under the age of 60 were signiﬁcantly more likely
to share this feeling. (Table 1).
Data Sharing, Consent, and Privacy
Despite the widespread privacy concerns described above,
73% of respondents said that they would deﬁnitely or
probably ‘‘sign a consent to provide past medical records’’
as part of the study. After adjustment for other demo-
graphic factors, black non-Hispanics (63%, p ¼ 0.001)
would be less likely than white non-Hispanics (74%) to
consent to provide past medical records, whereas those
earning more than $75,000 (78%, p ¼ 0.03) and those
with bachelor’s degrees (80%, p ¼ 3 3 106) would be
more likely to consent. Among those concerned withJournal of Human Genetics 85, 643–654, November 13, 2009 645
medical privacy, 70% would consent to provide past
medical records, compared to 81% of those unconcerned
about medical privacy (p ¼ 0.006). Only 56% of respon-
dents who said that they were afraid that study data could
be used against them would consent, compared to 83%
who were not afraid of data misuse (p ¼ 1 3 109). In a
Table 1. Survey Respondents’ Concerns about General Privacy and Issues of Privacy Related to the Large Cohort Study
Unweighted N
Concerned
about Privacy
of Their
Medical
Information
(%)
Concerned
about
Protecting
Their Privacy
in the
Study
(%)
Concerned
about
Study
Researchers
Having Their
Samples and
Information (%)
Concerned
about
Government
Having Their
Samples and
Information
(%)
Afraid that
Data Collected
by the Study
Could Be Used
against
Them
(%)
Total 4659 79 91 56 75 37
Gender
Men 2247 78 90 53 73 39
Women 2412 81 91 59a 78a 36
Race or Ethnic Group
White,
non-Hispanic
2798 77 91 53 74 35
Black,
non-Hispanic
774 89a 94 74a 84a 44a
Hispanic 867 79 87 56 79 41
American Indian
or Alaska Native
35 94a 91 52 71 41
Asian American
or Paciﬁc Islander
71 83 89 64a 69 45
2þ races 114 87a 93 52 73 45
Age Group
Age 18–29 838 71a 90 57 76 41
Age 30–44 1207 82 90 54 73 43
Age 45–59 1791 84 93 56 78 37
Age 60þ 823 79 89 57 75 28a
Education
< High-school 502 78 90 59 74 35
High school 1380 83 90 59 78 37
Some college 1406 78 92 58 78 38
Bachelor’s degree
or higher
1371 79 91 50a 70a 36
Household Income
< $25,000 959 78 91 62a 79 35
$25,000–$49,999 1499 81 89 57 77 39
$50,000–$74,999 1071 78 91 55 75 40
$75,000þ 1130 80 92 48 69a 34
Concerned about
privacy of medical
information
3694 100 95a 62a 81a 41a
Not concerned
about privacy of
medical
information
952 0 74 32 54 23
a This demographic category differs significantly from other categories in the group (p < 0.05), with correction for multiple comparisons among categories and
adjustment for all other variables shown in the table.646 The American Journal of Human Genetics 85, 643–654, November 13, 2009
logistic-regression model adjusting for concern about
medical privacy and fear that study data could be used
against them, black non-Hispanics (p ¼ 0.02) and those
without a bachelor’s degree (p ¼ 33 107) were still signif-
icantly less likely to consent to provide past medical
records.
A total of 82% said that they would deﬁnitely or prob-
ably ‘‘give blood for genetic and lab tests once during the
initial physical exam.’’ After adjustment for other demo-
graphic factors and for the fear that study data would
be used against them, black non-Hispanics (73%, p ¼
0.0005) and American Indians and Alaska Natives (65%,
p ¼ 0.03) would be less likely than white non-Hispanics
(83%) to consent to provide a blood sample. Women
(84% p ¼ 0.001), participants who self-identiﬁed as being
of two or more races (92%, p ¼ 0.006), those earning
more than $75,000 (88%, p ¼ 0.04), and those with bach-
elor’s degrees (87%, p ¼ 0.009) would be more likely to
provide a sample. A total of 71% of respondents who
said that they were afraid that study data could be used
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Figure 1. Percentage of Respondents Who Believe Specific
Types of Medical Information Deserve Extra Privacy Protections
Percentage of survey respondents who believe that various types of
information in a medical record need extra privacy protections,
among those who believe that some types of medical information
need extra protections (n ¼ 1574).The Americanagainst them would provide a sample, compared to 88%
who were not afraid of data misuse (p ¼ 1 3 109).
In addition to being asked about willingness to provide
past medical records and a blood sample, respondents
were asked what types of researchers should be allowed
to submit research projects for use of the biobank’s samples
and information (Table 2). A total of 92% would give
permission to academic and medical researchers, 80%
would allow government researchers to use the samples
and information, and 75% would allow pharmaceutical-
company researchers to use their samples and information.
Nearly half (49%) would be willing to have their deidenti-
ﬁed information and research results ‘‘made available on
the internet to anyone.’’
The purpose of the large cohort study would be to
provide a resource that researchers could use to study a
wide variety of phenotypes. Participants in the study
might be asked at the outset to provide consent that would
allow their samples to be used in all types of research
approved by the study, or they could be asked for consent
each time that a project that would use the biobank data is
approved. Respondents were asked for their preference
about how the cohort study should obtain consent to
share participants’ samples and information with re-
searchers. Nearly half (48%) would prefer to give permis-
sion once, at the beginning of the study, for all research
approved by an oversight panel. Slightly fewer (42%)
wanted to be asked permission for each research project
separately, and 10% preferred to select categories of
research (i.e., cancer or diabetes) for which they would or
would not let their samples be used.43 After adjustment
for demographic factors (Table 1), people who were con-
cerned about privacy were less likely to favor blanket
consent than were respondents who were not concerned
about the privacy of their medical records (45% versus
57%, p ¼ 0.0003). When respondents were questioned
about how being asked for consent for each study would
make them feel, 81% agreed that it would make them
feel ‘‘respected and involved,’’ and 74% agreed that they
would feel that they ‘‘had control.’’
Willingness to Participate in a National Cohort Study
Most survey respondents (84%) supported the general idea
of the large cohort study. At the conclusion of the survey,
each participant was randomly selected to view one of
eight different study scenarios, as described in theMethods
section (see Appendix, as well). With the responses to all
eight scenarios combined, 60% said that they deﬁnitely
or probably would be willing to participate in the study if
asked, given the scenario that they read. Support for the
study and willingness to participate did not vary substan-
tially across the demographic factors found in Table 1.41
Willingness to participate in the cohort studywas related
to the types of researchers that respondents would allow
access to their samples and information. For example,
66% of people who said that they would allow U.S.
academic researchers use of the collected data would beJournal of Human Genetics 85, 643–654, November 13, 2009 647
Table 2. Results of Multiple Logistic Regressions Examining Demographic Differences in Willingness to Share Data
‘‘I Would Allow These Researchers to Use My Samples and Information for Research.’’ ‘‘If I Could Not Be Identified,
I Would Be Willing to Have
My Information and Research
Results Available on the
Internet to Anyone.’’
Academic or
Medical Researchers
in the United States
Government-Funded
Researchers
Pharmaceutical-Company
Researchers
Agreea p Value Agreea p Value Agreea p Value Agreeb p Value
Gender
Men 92% 0.23 81% 0.39 75% 0.95 53% 0.01
Women 91% 78% 73% 45%
Household Income
$0–24,999 89% 0.004 77% 0.02 72% 0.47 49% 0.91
$25,000–
49,999
90% 76% 75% 47%
$50,000–
74,999
94% 80% 75% 48%
$75,000þ 95% 88% 77% 54%
Education
Bachelor’s
degree
or higher
95% 0.01 87% 0.0004 74% 0.40 53% 0.39
No bachelor’s
degree
90% 77% 75% 48%
Race or Ethnic Group
Black,
non-Hispanic
85% 0.004 71% 0.06 71% 0.07 49% 0.13
Hispanic 89% 0.47 78% 0.48 69% 0.04 46% 0.33
White,
non-Hispanic
93% reference 81% reference 76% reference 50% reference
All findings are adjusted for general concern about medical privacy and for concern about protecting privacy in the study. All p values are based on results of
multiple logistic regressions containing all covariates in the table, as well as age, which was entered into the models as a continuous variable.
a Percentage of respondents who agree with the statement ‘‘I would allow these researchers to use my samples and information for research.’’
b Percentage of respondents who agree with the statement ‘‘If I could not be identified, I would be willing to have my information and research results available on
the internet to anyone.’’willing to participate, compared to only 19% of those who
would not permit academics to use their data (adjusted
p< 13 109). Additionally, respondents whowere worried
that study results couldbeused against themwere less likely
to say that theywouldparticipate thanwere thosewhowere
not concerned (48% versus 68%, adjusted p ¼ 2 3 107).
Respondents who would be willing to have their ‘‘informa-
tion and research results made available on the internet to
anyone’’ if they could not be identiﬁed were more likely
to say that they would participate (75% versus 46%, p ¼
23106). After adjustment for survey respondents’willing-
ness to share information with academic researchers and
their concern about study data being used against them,
responses to questions about people’s general concern
about the privacy of medical information (p ¼ 0.29) and
about protection of privacy in the study (p ¼ 0.87) were
not associated with willingness to participate.
As Figure 2 shows, the relationship between concerns
about protecting one’s privacy in the study and willingness648 The American Journal of Human Genetics 85, 643–654, Novemto participate varied depending on the study beneﬁts in
the scenario that respondents were shown. Among people
shown the scenario in which cohort-study participants
would not receive individual research results and would
be given only $50 for their time, concerns about protection
of privacy were signiﬁcantly related to willingness to join
the study; those who were very concerned about protec-
tion of their privacy were signiﬁcantly less likely to say
that they would participate (47% versus 61%, respectively;
adjusted odds ratio [OR] ¼ 0.68, p ¼ 0.02). However,
among respondents who were told that they would re-
ceive $200 (OR comparing ‘‘very concerned’’ to ‘‘less con-
cerned’’ ¼ 0.96, p ¼ 0.82), those told that they would
receive individual research results (OR ¼ 0.92, p ¼ 0.68),
and those told they would receive both $200 and research
results (OR ¼ 0.90, p ¼ 0.64), there was no signiﬁcant
difference in willingness to participate between people
who were very concerned about protecting their privacy
and those with less concern.ber 13, 2009
Figure 2. The Relationship between Privacy Concerns and Willingness to Participate in Research When the Benefits of Participation
Vary
Relationship between concerns about protecting privacy in the large cohort study and willingness to participate in the study, under
differing scenarios of study beneﬁts.Nearly all respondents (93%) said that it would be some-
what or very important that it be illegal for insurers and
employers to get their study information, and 84% felt
that it would be important to have a law protecting
research information from law-enforcement ofﬁcials.
Concerns about one’s medical privacy (p ¼ 0.00002),
concerns about the government having access to samples
and information (p < 1 3 109), and fear that data
collected by the cohort study could be used against a study
participant (p ¼ 0.01) were all independently and signiﬁ-
cantly associated with support for a law barring access by
employers and insurers. Similarly, concern about the
government having access to samples and information
(p% 13 109) and general concern about medical privacy
(p ¼ 0.009) were associated with support for a law prohib-
iting access by law enforcement.
Conclusions
As has been observed in many other studies of privacy in
research, survey respondents in this study strongly valued
both privacy and participation in biomedical research.
Other studies of public attitudes have consistently shownThe Americanthat broad public support for biomedical research is often
balanced against concerns about maintaining conﬁdenti-
ality.17,44–46 Despite ubiquitous concerns about protection
of privacy among our survey respondents, six in ten would
participate in the large cohort study if asked, and most
would share their research data with academic, govern-
ment, and industry researchers. This ﬁnding agrees with
other surveys that observed that more than half of respon-
dents would be willing to share clinical data and samples
for research, provided that either the patients’ permission
would be sought beforehand or their data would be deiden-
tiﬁed to protect their privacy.44–53
Genetic information has been viewed by some scholars
as an exceptionally sensitive class of information,54 and
it has been targeted for speciﬁc heightened privacy protec-
tions.54 In this study, only 15% of those surveyed felt that
genetic test results were a class of medical information that
was especially sensitive and needed extra privacy protec-
tion. Although 37% did worry that data collected by the
study could be used against them, fear of genetic discrimi-
nation and the exceptional nature of genetic information
were not strongly supported here. It is striking that
although 90% of respondents were concerned about pro-
tecting their privacy, less than half that many said thatJournal of Human Genetics 85, 643–654, November 13, 2009 649
they feared that the data would be used against them. In
addition to being related to worries about discrimination
or loss of insurance, concerns about maintaining privacy
may be strongly related to issues of control over informa-
tion about oneself. The fact that large majorities agreed
that study-by-study consent would make them feel that
they were in control and respected by researchers supports
the notion that maintaining a sense of personal autonomy
may be as important as minimizing the harms that might
accrue from sharing personal information.
The issue of whom study data would be shared with was
a salient one. Survey respondents consistently were more
worried about government researchers and agencies ac-
cessing data from the cohort study than about academic
and medical researchers doing so. Sharing information
with pharmaceutical companies was even less palatable,
though it is unclear whether this was due to privacy
concerns or disapproval of the industry’s proﬁt motive.
These ﬁndings are consistent with several other studies
that observed that people aremore willing to sharemedical
information with academics than with govern-
ments17,33,35,50–52,55,56 or industries.17,48,51,53,55 As others
have suggested,19,57 this implies that informed-consent
documents should clarify, to the extent possible, what
types of researchers will have access to study data.
General concerns about the protection of privacy in the
study were not signiﬁcantly related to people’s stated will-
ingness to participate in the large cohort study, but some
speciﬁc beliefs related to privacy were correlated with will-
ingness to join the study. The 37% who feared that study
data could be used against them were signiﬁcantly less
likely to join the cohort study, but nearly half would partic-
ipate despite this fear. Although the respondents who
would not let academic researchers apply for use of the
cohort data were signiﬁcantly less likely to say that they
would join the study, this group included only 8% of
respondents, so this unwillingness seems unlikely to
have a particularly large overall impact. Several studies of
the importance of privacy and consent in genetic research
participation have observed high rates of willingness to
participate in genetic research despite broad general
concerns about privacy. A Singapore-based survey found
that people who were less concerned about privacy were
more willing to donate a blood sample for genetic research,
but privacy concerns were less important to people than
the perceived societal beneﬁts of participation.35 Members
of a genetic study of epilepsy felt that it was important to
have general control over access to their DNA, but under-
stood that not agreeing to a full release of the data could
compromise the utility of the data set.17 A Swedish study
found that 86% of participants would donate a blood
sample and information to a secure database linked to
personal identiﬁers and that only 3% more would partici-
pate if the data were delinked.36 Another study found
that similar percentages of people would be willing to
participate in genetic studies whether the studies used
identiﬁable or deidentiﬁed data.37650 The American Journal of Human Genetics 85, 643–654, NovemThe relationship between general privacy concerns and
willingness to participate in genetic research may be of
most signiﬁcance in recruiting a representative sample.
People who have not completed a college education and
members of the black non-Hispanic community were
observed to have greater privacy concerns across several
privacy-related questions. Efforts to enhance both overall
privacy protections and the information that people in
these demographic groups receive about such efforts may
be of particular use in minimizing selection biases due to
differential levels of concern.
Although this survey does not explain with certainty
why pervasive privacy concerns do not translate into
more inhibition about participation in research, the data
suggest at least two possible explanations. One possibility,
echoed in other studies, is that although peoplemay recog-
nize the risk of signiﬁcant loss of privacy if they participate,
they may also recognize and accept that their privacy
cannot be guaranteed despite researchers’ best efforts.48
Many people may be willing to accept the risks that they
feel remain. For example, respondents to our survey may
have gained conﬁdence in the ability of the large cohort
study to protect their privacy because they were told that
their data would be coded before being entered into the
database, that a committee would oversee who is allowed
the use of the data, and that they might be able to consent
for each use of their data. It may also be that people under-
estimate the extent to which their data will be shared by
biobanks.14–17
A second possible explanation for the observation that
ubiquitous privacy concerns are not strongly related to
willingness to join a research study is that formany people,
the perceived potential risk of a loss of privacy is overcome
by the beneﬁts of participating in such research. Generally
speaking, there are very few individual beneﬁts to partici-
pating in a biobank or observational cohort study. Beneﬁts
might include monetary compensation for a participant’s
time or the return of health information or research ﬁnd-
ings from the study. Although such beneﬁts do nothing
to mitigate the actual risk of suffering a loss of privacy,
our survey offers some evidence that modest payment or
the return of individual research results may outweigh
some people’s privacy concerns as they decide whether
or not to participate in such research.
The notion that payment or return of health informa-
tion can outweigh a person’s privacy concerns may have
implications for the ethical enrollment of subjects. When
considering issues of privacy, the ﬁrst goal of a researcher
should be to protect research participants to the greatest
extent that is practically possible. However, once these
protections have been put in place, it is not clear that
providing health information or a reasonable, fair incen-
tive is ethically wrong simply because some people view
it as a sufﬁcient counterbalance to their remaining privacy
concerns. For many people, their simple desire to con-
tribute to research will be sufﬁcient to overcome their
privacy concerns—for example, in Figure 2, 47% of thoseber 13, 2009
who said that they would be very concerned about their
privacy would participate even when offered the lower
level of compensation and no individual research results.
However, it would seem odd to forbid recruiters from
mentioning the potential societal beneﬁts of research
participation because of concerns that doing so might be
coercive. For many people, concerns about privacy may
not be an absolute deal-breaker that precludes participa-
tion in research but, rather, may be one of a list of several
pros and cons that are weighted in deciding whether or not
to participate. If the information or incentives to be given
to participants are deemed appropriate to the risks and
burden of participation, it may be acceptable that they
tip the balance toward participation for some people who
are concerned about privacy.
It should be emphasized that people’s responses on a
cross-sectional survey about participation in a hypothetical
study will not necessarily correlate with actual behaviors in
real situations at a different point in time. This study is able
to provide valid estimates of the relationships between
concerns about privacy, study-design factors, and people’s
willingness to participate, but is likely to be less accurate in
estimating actual participation rates. Additionally, this
survey was ﬁelded before the passage of the Genetic Infor-
mation Nondiscrimination Act of 2008 (GINA), which
prevents health insurers and employers from denying
coverage, adjusting premiums, or otherwise discriminating
on the basis of genetic information.58,59 With the passage
and implementation of GINA, the risks and potential
harms of misuse of genetic research data will decrease.
However, changes in public perceptions of these risks
may lag behind these legislative advances, and researchers
should be prepared to address ongoing privacy concerns
about the potential misuse of both genetic and nongenetic
medical information.
The actions that the public views as serious misuses of
study data, the people whom they deem most likely to
commit these actions, and what they believe could or
should be done to improve the public trust and prevent
such actions are all closely related topics that warrant addi-
tional attention and further research. Changes in the land-
scape of privacy risks and protections have occurred since
the survey was ﬁelded, including the passage of GINA, the
emergence of newmethods enabling reidentiﬁcation of de-
identiﬁed study data through DNA, the increased publica-
tion of genotype data inmanuscripts of genome-wide asso-
cation studies, and the increased use of electronic medical
records. The effects of these changes on public views of the
privacy risks associated with participation in biobanks or
biomedical research warrant further investigation.
Regardless of what such research might ﬁnd, the results
of this study support the argument that during the consent
process, potential research participants should be told
about the different levels of deidentiﬁcation of data that
are possible,10 the fact that studies including DNA may
not be completely deidentiﬁable, explicit details of the
protections offered by the study protocol, and the privacyThe Americarisks that remain.57,60–62 In addition to providing research
participants with transparent, forthright explanations of
the privacy risks that they may face, consent documents
should detail what data could be gathered through study
protocols, whom the data could be shared with, how the
data might be analyzed, and what formats the data are
likely be published in. The desire of research participants
to know what risks they face up front will be satisﬁed,
and trust, based on an honest assessment of risks and
protections, may be established between researchers and
those who choose to participate.
In addition to clear communications of outlying privacy
risks that accompany participation in research, the
research enterprise must work to fortify the protections
that it offers participants. Policies about the publication
of and public access to deidentiﬁed data that include
genetic sequences should be reviewed by parties that share
or publish such data. Researchers should be encouraged to
use certiﬁcates of conﬁdentiality to protect participants
from forced disclosure of their identities for use in civil,
criminal, administrative, or legislative proceedings. The
NIH should consider adoption of a different model of
certiﬁcate of conﬁdentiality, such as the one used by
researchers at the U.S. Department of Justice that does
not permit the researcher discretion about whether to
release study information to law-enforcement ofﬁcials
and instead forbids studies with certiﬁcates from all such
disclosures. It may also be worthwhile to examine what
practices researchers and data-access committees of bio-
banks and large cohort studies are using to maintain
privacy, where they view vulnerabilities, and what prob-
lems they have experienced or observed in protecting
subjects’ privacy, because research practitioners may iden-
tify problems and potential solutions long before policy
makers become aware that the problems exist.
Appendix: Definition of Individual Research
Results and Scenario Variables Used
in the Pilot Study
Deﬁnition of Individual Research Results
The following text was used in the survey as an explana-
tion of the concept of individual research results for survey
participants:
Blood samples would be sent to a lab, where a genetic anal-
ysis would be done. Genetic and medical information would
be stored in a databank. Researchers could apply to use the
samples and information to study genes, environment, and life-
style.
Researchers might ﬁnd that a certain genetic, environmental
or lifestyle factor is related to a speciﬁc disease. This kind of
general study ﬁnding would be released to the public.
An individual participant’s research result would be the infor-
mation researchers ﬁnd about whether the person had a speciﬁc
genetic, environmental, or lifestyle risk factor. These individual
research results would not be released to the public.n Journal of Human Genetics 85, 643–654, November 13, 2009 651
Scenarios Used in Pilot Study Instrument
Each survey respondent viewed one of eight randomly
selected scenarios that varied with respect to three factors:
the burden of the cohort study that they would be asked to
participate in, the amount of compensation that they
would receive, and whether or not they would receive
individual research results back. There were two versions
of each factor, resulting in eight possible scenarios:
(1) Higher Burden, Higher Compensation, No Indi-
vidual Research Results
(2) Higher Burden, Higher Compensation, Individual
Research Results Returned
(3) Higher Burden, Lower Compensation, No Indi-
vidual Research Results
(4) Higher Burden, Lower Compensation, Individual
Research Results Returned
(5) Lower Burden, Higher Compensation, No Indi-
vidual Research Results
(6) Lower Burden, Higher Compensation, Individual
Research Results Returned
(7) Lower Burden, Lower Compensation, No Individual
Research Results
(8) Lower Burden, Lower Compensation, Individual
Research Results Returned
The alternate versions of the three factors were deﬁned
as follows:
Lower Burden: Let’s say the study is going forward and you
were invited to participate. At the beginning of the study, you
would be asked to travel to a local health clinic for one half day
of exams. Youwould provide samples (blood, urine, etc.) for labo-
ratory tests and ﬁll out questionnaires on your health, diet and
lifestyle. In addition, you would be asked to complete a health
assessment questionnaire once a year for the next ten years.
Higher Burden: Let’s say the study is going forward and you
were invited to participate. At the beginning of the study, you
would be asked to travel to a local health clinic for one half
day of exams. You would provide samples (blood, urine, etc.)
for laboratory tests and ﬁll out questionnaires on your health,
diet and lifestyle. Researchers would come to your home to
collect environmental samples and to place a device to monitor
air quality. You would be asked keep a diet and exercise journal
for one week and to complete a health assessment questionnaire
once a year for the next ten years.
Receive Research Results: You would receive results from
your initial physical examination and laboratory tests. You
would also receive general research ﬁndings from the study.
You could also ﬁnd out your individual research results if you
wanted to.
Do Not Receive Research Results: You would receive results
from your initial physical examination and laboratory tests. You
would also receive general research ﬁndings from the study.
However, you would not be given any individual research results.
Lower Compensation: The study would reimburse you for
the cost of any travel to and from the initial exam. You would
receive $50 to compensate you for time spent at the initial exam.652 The American Journal of Human Genetics 85, 643–654, NovembHigher Compensation: The study would reimburse you for
the cost of any travel to and from the initial exam. You would
receive $200 to compensate you for time spent at the initial
exam and an additional $20 for each completed health-assess-
ment questionnaire.
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